• All doses of Novo Nordisk’s Wegovy weight loss injection and diabetes drug Ozempic are now available in the United States, according to an update to the FDA’s drug shortage database.
• It’s a sign that Novo Nordisk’s efforts to increase the supply of these drugs are starting to bear fruit, as demand continues to soar in the United States.
• The update raises the possibility of the FDA removing blockbuster shots from its shortage list altogether, which could prevent compounding pharmacies from making customized and often cheaper versions of these brand-name drugs.

All doses of Novo NordiskThe very popular weight loss injection of Wegovy and diabetes drug Ozempic are now available in the United States, according to a update based on drug shortage data from the U.S. Food and Drug Administration on Wednesday.

This is a sign that Novo Nordisk’s efforts to increase supply of these weekly drugs are starting to pay off, as demand continues to soar in the United States

A previous update said Wegovy’s lowest dose — 25 milligrams — was still rare.

Multiple doses of semaglutide, the active ingredient in Wegovy and Ozempic, have been on the FDA’s shortage list since early 2022, as demand has skyrocketed in the United States.

Wednesday’s update raises the possibility that the FDA will remove the blockbuster shots from its shortage list altogether, which could prevent compounding pharmacies from making customized and often cheaper versions of these brand-name drugs.

In a statement, Novo Nordisk said all doses from Wegovy and Ozempic were being shipped regularly to wholesalers. The Danish drugmaker said the FDA update was the result of its significant investment in expanding its manufacturing capacity and its “continuous communication” with the agency.

Nonetheless, Novo Nordisk said patients are not always able to immediately fill their prescriptions at a particular pharmacy, even when a drug is listed as available.

“Our intentional approach of gradually increasing supply to the US market is working,” Novo Nordisk said. “We will continue to prioritize continuity of care for patients, closely monitoring market dynamics and prescribing trends throughout the process.”

This comes a week after Novo Nordisk asked the FDA to prevent compounding pharmacies to make unapproved versions of Wegovy and Ozempic, arguing that the drugs are too complex for those manufacturers to make safely.

Earlier this month, the FDA removed tirzepatide, the active ingredient from Elie LillyIt is Zepbound weight loss medication and diabetes treatment Mounjaro, from its shortage list. But a trade group representing some compounders sued the FDA, leading the agency to announce that it would reconsider its decision to remove tirzepatide from its list of shortage products.